https://www.corsairpharma.com/corsair-pharma-announces-appointment-of-george-w-mahaffey-as-chief-executive-officer/ 2026-06-02T13:05:38+00:00 https://www.corsairpharma.com/corsair-pharma-announces-successful-completion-of-preclinical-program-for-its-treprostinil-prodrug-transdermal-system/ 2026-06-02T13:17:58+00:00 https://www.corsairpharma.com/corsair-pharma-to-present-new-data-on-proprietary-treprostinil-prodrug-transdermal-system-at-phpn-2025-symposium/ 2026-06-02T13:19:01+00:00 https://www.corsairpharma.com/wp-content/uploads/2026/05/AdobeStock_135412625-1-1-1.webp https://www.corsairpharma.com/corsair-pharma-announces-23-million-series-b-financing-to-advance-clinical-trials-in-pah/ 2026-06-02T13:19:07+00:00 https://www.corsairpharma.com/corsair-pharma-announces-positive-phase-1-results-for-the-trx-248-transdermal-system-in-pulmonary-arterial-hypertension/ 2026-06-03T11:17:15+00:00 https://www.corsairpharma.com/corsair-pharma-announces-three-presentations-of-phase-1-clinical-data-for-trx-248-transdermal-system-at-the-2026-pulmonary-hypertension-association-conference/ 2026-06-08T11:22:31+00:00 https://www.corsairpharma.com/corsair-united-therapeutics-enter-strategic-collaboration-to-advance-novel-treprostinil-prodrugs/ 2026-06-08T17:51:07+00:00